Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiomolibdate choline - Monopar Therapeutics

Next Previous
Drug Profile

Tiomolibdate choline - Monopar Therapeutics

Alternative Names: ALXN-1840; ATN-224; Bis(choline)tetrathiomolybdate; Bis-choline tetrathiomolybdate; Decuprate; WTX-101

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer Alexion AstraZeneca Rare Disease; Attenuon; Cancer Research UK
  • Class Antineoplastics; Heavy metals; Neuroprotectants; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatolenticular degeneration; Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatolenticular degeneration
  • No development reported Amyotrophic lateral sclerosis
  • Discontinued Breast cancer; Malignant melanoma; Multiple myeloma; Prostate cancer; Solid tumours

Most Recent Events

  • 31 Mar 2025 AstraZeneca plans to file a regulatory submission for Hepatolenticular degeneration (PO) in early 2026
  • 14 Nov 2024 Monopar Therapeutics plans a meeting with the US FDA
  • 24 Oct 2024 Tiomolibdate choline is still in phase II trials for Hepatolenticular degeneration in Germany, Austria, Poland, United Kingdom, Belgium, Canada, Denmark, Australia, France, New Zealand, Poland, Russia, Serbia, Singapore, South Korea, Spain, Sweden, Turkey and USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top